INCY has been sideways for a year, but it is not showing a compression candlestick pattern to a potential Triangle Formation. Triangles tend to be continuation patterns much of the time.
INCY is rated "strong buy" doesn't mean too much, but price is showing signs of an overall oscillating pattern with peaks forming near a common RSI level around 60. Price is also trading above the SMA200 on the daily chart, signaling potential bullish movement. Friday's close created a large Bullish Candlestick that broke above & closed above both the SMA50 and...
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute...
Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging...
SMA and EMA crossed. MACD crossed. The technical setup is looking very nice assuming you get a decent entry.
Stop Loss: $77.29
Exit 1: $72.27
Exit 2: $68.02
Incyte Corp. has overlapping white candles on a strong move out of a short-term bottom. The overlaps are caused by pre-market open selling that gaps the stock down. The run up shows strength within the buy side.
The prices are making a pullback on the 200 daily SMA. The IN area in my opinion is the green box with tight stop loss due the RSI value. From the green box LONG until the prices will be on the 200 daily SMA
double bottom bullish divergence.. island reversal somewhere to the end of the year? need to open once above $80 without touching the gap between.
1W RSI was approx in 2008 as low as in May at the current year.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
INCY
![INCY: [INCY] phase 1](https://s3.tradingview.com/0/08glyUW4_mid.png "[INCY] phase 1")
